Associations of sarcopenia with graft failure and mortality in patients undergoing living donor liver transplantation

Ji‐Hoon Sim, Hye‐Mee Kwon, Kyung‐Won Kim, You‐Sun Ko, In‐Gu Jun, Sung‐Hoon Kim, Kyoung‐Sun Kim, Young‐Jin Moon, Jun‐Gol Song, Gyu‐Sam Hwang – 3 March 2022 – Recent studies have reported that sarcopenia influences morbidity and mortality in surgical patients. However, few studies have investigated the associations of sarcopenia with short‐term and long‐term graft failure in recipients after living donor liver transplantation (LDLT). In this study, we investigated the associations between sarcopenia and graft failure/mortality in patients undergoing LDLT.

mRNA and gene editing: Late breaking therapies in liver diseases

Nerea Zabaleta, Laura Torella, Nicholas D. Weber, Gloria Gonzalez‐Aseguinolaza – 3 March 2022 – The efficient delivery of RNA molecules to restore the expression of a missing or inadequately functioning protein in a target cell and the intentional specific modification of the host genome using engineered nucleases represent therapeutic concepts that are revolutionizing modern medicine.

Ten‐eleven translocation‐2 inactivation restrains IL‐10‐producing regulatory B cells to enable antitumor immunity in hepatocellular carcinoma

Zhou Lu, Ronghua Liu, Yining Wang, Mengxia Jiao, Zhongchen Li, Zhiqiang Wang, Cheng Huang, Guoming Shi, Aiwu Ke, Luman Wang, Ying Fu, Jie Xia, Haoyu Wen, Jian Zhou, Xiaoying Wang, Dan Ye, Jia Fan, Yiwei Chu, Jiabin Cai – 3 March 2022

Integrin subunit beta 8 contributes to lenvatinib resistance in HCC

Wei Hou, Bryan Bridgeman, Greg Malnassy, Xianzhong Ding, Scott J. Cotler, Asha Dhanarajan, Wei Qiu – 2 March 2022 – Lenvatinib is a multikinase inhibitor approved as a first‐line therapy for advanced hepatocellular carcinoma (HCC). However, the development of drug resistance is common, and the underlying mechanisms governing this resistance are largely unknown. In this study, we established two lenvatinib‐resistant (LR) HCC cell lines and identified integrin subunit beta 8 (ITGB8) as a critical contributor to lenvatinib resistance in HCC.

A pilot study of vidofludimus calcium for treatment of primary sclerosing cholangitis

Elizabeth J. Carey, John Eaton, Mitchell Clayton, Andrea Gossard, Sara Iqbal, Hamid Ullah, Nan Zhang, Richard Butterfield, Keith D. Lindor – 2 March 2022 – The purpose of this pilot study was to explore the efficacy, safety, and tolerability of vidofludimus calcium (VC) in the treatment of primary sclerosing cholangitis (PSC). This was a single‐arm open‐label pilot study with a cohort of 18 patients with PSC. Study patients received VC for a period of 6 months. The study was undertaken at two sites, Mayo Clinic, Rochester, MN, and Mayo Clinic, Phoenix, AZ.

Subscribe to